TY - JOUR AU - Sorm, F. AU - Piskala, A. AU - Cihak, A. AU - Vesely, J. PY - 1964 DA - 1964// TI - 5-Azacytidine, a new, highly effective cancerostatic JO - Experientia VL - 20 UR - https://doi.org/10.1007/BF02135399 DO - 10.1007/BF02135399 ID - Sorm1964 ER - TY - JOUR AU - Jones, P. A. AU - Taylor, S. M. PY - 1980 DA - 1980// TI - Cellular differentiation, cytidine analogs and DNA methylation JO - Cell VL - 20 UR - https://doi.org/10.1016/0092-8674(80)90237-8 DO - 10.1016/0092-8674(80)90237-8 ID - Jones1980 ER - TY - JOUR AU - Hoff, D. D. AU - Slavik, M. AU - Muggia, F. M. PY - 1976 DA - 1976// TI - 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia JO - Ann Intern Med VL - 85 UR - https://doi.org/10.7326/0003-4819-85-2-237 DO - 10.7326/0003-4819-85-2-237 ID - Hoff1976 ER - TY - JOUR AU - Jones, P. A. AU - Taylor, S. M. PY - 1981 DA - 1981// TI - Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells JO - Nucleic Acids Res VL - 9 UR - https://doi.org/10.1093/nar/9.12.2933 DO - 10.1093/nar/9.12.2933 ID - Jones1981 ER - TY - STD TI - Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–40. ID - ref5 ER - TY - JOUR AU - Voso, M. T. AU - Scardocci, A. AU - Guidi, F. PY - 2004 DA - 2004// TI - Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelo-dysplastic syndromes JO - Blood VL - 103 UR - https://doi.org/10.1182/blood-2003-07-2249 DO - 10.1182/blood-2003-07-2249 ID - Voso2004 ER - TY - JOUR AU - Lübbert, M. AU - Suciu, S. AU - Baila, L. PY - 2011 DA - 2011// TI - Low-Dose decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation forResearch and Treatment of Cancer Leukemia Group and the German MDS Study Group JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.30.9245 DO - 10.1200/JCO.2010.30.9245 ID - Lübbert2011 ER - TY - JOUR AU - Kantarjian, H. AU - Oki, Y. AU - Garcia-Manero, G. PY - 2007 DA - 2007// TI - Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia JO - Blood VL - 109 UR - https://doi.org/10.1182/blood-2006-05-021162 DO - 10.1182/blood-2006-05-021162 ID - Kantarjian2007 ER - TY - JOUR AU - Rius, M. AU - Stresemann, C. AU - Keller, D. PY - 2009 DA - 2009// TI - Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation JO - Mol Cancer Ther VL - 8 UR - https://doi.org/10.1158/1535-7163.MCT-08-0743 DO - 10.1158/1535-7163.MCT-08-0743 ID - Rius2009 ER - TY - JOUR AU - Li, L. H. AU - Olin, E. J. AU - Buskirk, H. H. AU - Reineke, L. M. PY - 1970 DA - 1970// TI - Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia JO - Cancer Res VL - 30 ID - Li1970 ER - TY - JOUR AU - Leonhardt, H. AU - Page, A. W. AU - Weier, H. U. AU - Bestor, T. H. PY - 1992 DA - 1992// TI - A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei JO - Cell VL - 71 UR - https://doi.org/10.1016/0092-8674(92)90561-P DO - 10.1016/0092-8674(92)90561-P ID - Leonhardt1992 ER - TY - JOUR AU - Liu, K. AU - Wang, Y. F. AU - Cantemir, C. AU - Muller, M. T. PY - 2003 DA - 2003// TI - Endogenous assays of DNA methyltransferases: Evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells in vivo JO - Mol Cell Biol VL - 23 UR - https://doi.org/10.1128/MCB.23.8.2709-2719.2003 DO - 10.1128/MCB.23.8.2709-2719.2003 ID - Liu2003 ER - TY - JOUR AU - Taylor, S. M. AU - Jones, P. A. PY - 1982 DA - 1982// TI - Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosinecontaining DNA JO - J Mol Biol VL - 162 UR - https://doi.org/10.1016/0022-2836(82)90395-3 DO - 10.1016/0022-2836(82)90395-3 ID - Taylor1982 ER - TY - JOUR AU - Bender, C. M. AU - Zingg, J. M. AU - Jones, P. A. PY - 1998 DA - 1998// TI - DNA methylation as a target for drug design JO - Pharm Res VL - 15 UR - https://doi.org/10.1023/A:1011946030404 DO - 10.1023/A:1011946030404 ID - Bender1998 ER - TY - JOUR AU - Juttermann, R. AU - Li, E. AU - Jaenisch, R. PY - 1994 DA - 1994// TI - Toxicity of 5-aza-2_-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation JO - Proc Natl Acad Sci U S A VL - 91 UR - https://doi.org/10.1073/pnas.91.25.11797 DO - 10.1073/pnas.91.25.11797 ID - Juttermann1994 ER - TY - JOUR AU - Palii, S. S. AU - Emburgh, B. O. AU - Sankpal, U. T. PY - 2008 DA - 2008// TI - DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B JO - Mol Cell Biol VL - 28 UR - https://doi.org/10.1128/MCB.01799-07 DO - 10.1128/MCB.01799-07 ID - Palii2008 ER - TY - JOUR AU - Orta, M. L. AU - Höglund, A. AU - Calderón-Montaño, J. M. PY - 2014 DA - 2014// TI - The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2'-deoxycytidine lesions JO - Nucleic Acids Res VL - 42 UR - https://doi.org/10.1093/nar/gku638 DO - 10.1093/nar/gku638 ID - Orta2014 ER - TY - JOUR AU - Mortusewicz, O. AU - Schermelleh, L. AU - Walter, J. PY - 2005 DA - 2005// TI - Recruitment of DNA methyltransferase I to DNA repair sites JO - Proc Natl Acad Sci U S A VL - 102 UR - https://doi.org/10.1073/pnas.0501034102 DO - 10.1073/pnas.0501034102 ID - Mortusewicz2005 ER - TY - JOUR AU - Vispé, S. AU - Deroide, A. AU - Davoine, E. PY - 2015 DA - 2015// TI - Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cells JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.3317 DO - 10.18632/oncotarget.3317 ID - Vispé2015 ER - TY - JOUR AU - Lee, T. T. AU - Karon, M. R. PY - 1976 DA - 1976// TI - Inhibition of protein synthesis in 5-azacytidine-treated HeLa cells JO - Biochem Pharmacol VL - 25 UR - https://doi.org/10.1016/0006-2952(76)90407-X DO - 10.1016/0006-2952(76)90407-X ID - Lee1976 ER - TY - JOUR AU - Lu, L. J. W. AU - Randerath, K. PY - 1980 DA - 1980// TI - Mechanism of 5-azacytidine-induced transfer RNA cytosine-5-methyltransferase deficiency JO - Cancer Res VL - 40 ID - Lu1980 ER - TY - JOUR AU - Schaefer, M. AU - Hagemann, S. AU - Hanna, K. AU - Lyko, F. PY - 2009 DA - 2009// TI - Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-09-0458 DO - 10.1158/0008-5472.CAN-09-0458 ID - Schaefer2009 ER - TY - JOUR AU - Aimiuwu, J. AU - Wang, H. AU - Chen, P. PY - 2012 DA - 2012// TI - RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-11-382226 DO - 10.1182/blood-2011-11-382226 ID - Aimiuwu2012 ER - TY - JOUR AU - Chiappinelli, K. B. AU - Strissel, P. L. AU - Desrichard, A. PY - 2015 DA - 2015// TI - Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses JO - Cell VL - 162 UR - https://doi.org/10.1016/j.cell.2015.07.011 DO - 10.1016/j.cell.2015.07.011 ID - Chiappinelli2015 ER - TY - JOUR AU - Li, H. AU - Chiappinelli, K. B. AU - Guzzetta, A. A. AU - Easwaran, H. PY - 2014 DA - 2014// TI - Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers JO - Oncotarget VL - 5 UR - https://doi.org/10.18632/oncotarget.1782 DO - 10.18632/oncotarget.1782 ID - Li2014 ER - TY - JOUR AU - Wrangle, J. AU - Wang, W. AU - Koch, A. PY - 2013 DA - 2013// TI - Alterations of immune response of non-small cell lung cancer with azacytidine JO - Oncotarget VL - 4 UR - https://doi.org/10.18632/oncotarget.1542 DO - 10.18632/oncotarget.1542 ID - Wrangle2013 ER - TY - JOUR AU - Fabre, C. AU - Grosjean, J. AU - Tailler, M. PY - 2008 DA - 2008// TI - A novel effect of DNA methyltransferase and histone deacetylase inhibitors: nfkappab inhibition in malignant myeloblasts JO - Cell Cycle VL - 7 UR - https://doi.org/10.4161/cc.7.14.6268 DO - 10.4161/cc.7.14.6268 ID - Fabre2008 ER - TY - JOUR AU - Costantini, B. AU - Kordasti, S. Y. AU - Kulasekararaj, A. G. PY - 2011 DA - 2011// TI - 5-azacytidine specifically depletes regulatory t cells (tregs) in myelodysplastic syndrome (mds) patients JO - ASH Annual, Meeting Abstracts VL - 118 ID - Costantini2011 ER - TY - JOUR AU - Cihák, A. PY - 1974 DA - 1974// TI - Biological effects of 5-azacytidine in eukaryotes JO - Oncology VL - 30 UR - https://doi.org/10.1159/000224981 DO - 10.1159/000224981 ID - Cihák1974 ER - TY - JOUR AU - Poirier, S. AU - Samami, S. AU - Mamarbachi, M. PY - 2014 DA - 2014// TI - The Epigenetic Drug 5-Azacytidine Interferes with Cholesterol and Lipid Metabolism JO - J Biol Chem VL - 289 UR - https://doi.org/10.1074/jbc.M114.563650 DO - 10.1074/jbc.M114.563650 ID - Poirier2014 ER - TY - JOUR AU - Vesely, J. PY - 1985 DA - 1985// TI - Mode of action and effects of 5-azacytidine and of its derivatives in eukaryotic cells JO - Pharmacol Ther VL - 28 UR - https://doi.org/10.1016/0163-7258(85)90012-9 DO - 10.1016/0163-7258(85)90012-9 ID - Vesely1985 ER - TY - JOUR AU - Glover, A. B. AU - Leyland-Jones, B. PY - 1987 DA - 1987// TI - Biochemistry of azacytidine: a review JO - Cancer Treat Rep VL - 71 ID - Glover1987 ER - TY - JOUR AU - Chabner, B. A. AU - Drake, J. C. AU - Johns, D. G. PY - 1973 DA - 1973// TI - Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase JO - Biochem Pharmacol VL - 22 UR - https://doi.org/10.1016/0006-2952(73)90137-8 DO - 10.1016/0006-2952(73)90137-8 ID - Chabner1973 ER - TY - JOUR AU - Voso, M. T. AU - Breccia, M. AU - Lunghi, M. PY - 2013 DA - 2013// TI - Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia JO - Eur J Haematol VL - 90 UR - https://doi.org/10.1111/ejh.12079 DO - 10.1111/ejh.12079 ID - Voso2013 ER - TY - JOUR AU - Liu, Z. AU - Marcucci, G. AU - Byrd, J. C. PY - 2006 DA - 2006// TI - Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-20-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method JO - Rapid Commun Mass Spectrom VL - 20 UR - https://doi.org/10.1002/rcm.2423 DO - 10.1002/rcm.2423 ID - Liu2006 ER - TY - JOUR AU - Marcucci, G. AU - Silverman, L. AU - Eller, M. PY - 2005 DA - 2005// TI - Bioavailabilit of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes JO - J Clin Pharmacol VL - 45 UR - https://doi.org/10.1177/0091270004271947 DO - 10.1177/0091270004271947 ID - Marcucci2005 ER - TY - JOUR AU - Stresemann, C. AU - Bokelmann, I. AU - Mahlknecht, U. AU - Lyko, T. PY - 2008 DA - 2008// TI - Therapeutics, Targets, and Development: Azacytidine causes complex DNA methylation responses in myeloid leukemia JO - Mol Cancer Ther September VL - 7 UR - https://doi.org/10.1158/1535-7163.MCT-08-0411 DO - 10.1158/1535-7163.MCT-08-0411 ID - Stresemann2008 ER - TY - JOUR AU - Yang, A. S. AU - Doshi, K. D. AU - Choi, S. W. PY - 2006 DA - 2006// TI - DNA methylation changes after 5-aza-20-deoxycytidine therapy in patients with leukemia JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-05-2385 DO - 10.1158/0008-5472.CAN-05-2385 ID - Yang2006 ER - TY - JOUR AU - Adams, R. L. AU - Fulton, J. AU - Kirk, D. PY - 1982 DA - 1982// TI - The effect of 5-azadeoxycytidine on cell growth and DNA methylation JO - Biochim Biophys Acta VL - 697 UR - https://doi.org/10.1016/0167-4781(82)90091-4 DO - 10.1016/0167-4781(82)90091-4 ID - Adams1982 ER - TY - JOUR AU - Momparler, R. L. AU - Momparler, L. F. AU - Samson, J. PY - 1984 DA - 1984// TI - Comparison of the antileukemic activity of 5-aza-2'-deoxycytidine, 1-ß-D-arabinofuranosyl-cytosine and 5-azacytidine against L1210 leukemia JO - Leukemia Res VL - 8 UR - https://doi.org/10.1016/0145-2126(84)90059-6 DO - 10.1016/0145-2126(84)90059-6 ID - Momparler1984 ER - TY - JOUR AU - Momparler, R. L. AU - Rossi, M. AU - Bouchard, J. PY - 1984 DA - 1984// TI - Kinetic interaction of 5-AZA-2'-deoxycytidine-5'-monophosphate and its 5'-triphosphate with deoxycytidylate deaminase JO - Mol Pharmacol VL - 25 ID - Momparler1984 ER - TY - JOUR AU - Momparler, R. L. AU - Onetto-Pothier, N. AU - Momparler, L. F. PY - 1990 DA - 1990// TI - Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype JO - Leuk Res VL - 14 UR - https://doi.org/10.1016/0145-2126(90)90068-K DO - 10.1016/0145-2126(90)90068-K ID - Momparler1990 ER - TY - JOUR AU - Covey, J. M. AU - Zaharko, D. S. PY - 1985 DA - 1985// TI - Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2'-deoxycytidine with its therapeutic and toxic effects in mice JO - Eur J Cancer Clin Oncol VL - 21 UR - https://doi.org/10.1016/0277-5379(85)90207-X DO - 10.1016/0277-5379(85)90207-X ID - Covey1985 ER - TY - JOUR AU - Issa, J. P. AU - Garcia-Manero, G. AU - Giles, F. J. PY - 2004 DA - 2004// TI - Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies JO - Blood VL - 103 UR - https://doi.org/10.1182/blood-2003-03-0687 DO - 10.1182/blood-2003-03-0687 ID - Issa2004 ER - TY - JOUR AU - Jabbour, E. AU - Cortes, J. E. AU - Kantarjian, H. M. PY - 2008 DA - 2008// TI - Molecular monitoring in chronic myeloidleukemia: response to tyrosine kinase inhibitors and prognostic implications JO - Cancer VL - 112 UR - https://doi.org/10.1002/cncr.23427 DO - 10.1002/cncr.23427 ID - Jabbour2008 ER - TY - JOUR AU - Hollenbach, P. W. AU - Nguyen, A. N. AU - Brady, H. PY - 2010 DA - 2010// TI - A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines JO - PLoS One VL - 5 UR - https://doi.org/10.1371/journal.pone.0009001 DO - 10.1371/journal.pone.0009001 ID - Hollenbach2010 ER - TY - JOUR AU - Greenberg, P. L. AU - Stone, R. M. AU - Bejar, R. PY - 2015 DA - 2015// TI - Myelodysplastic syndromes, version 2.2015 JO - J Natl Compr Canc Netw VL - 13 ID - Greenberg2015 ER - TY - JOUR AU - Fenaux, P. AU - Mufti, G. J. AU - Hellstrom-Lindberg, E. PY - 2009 DA - 2009// TI - Efficacy of azacytidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study JO - Lancet Oncol VL - 10 UR - https://doi.org/10.1016/S1470-2045(09)70003-8 DO - 10.1016/S1470-2045(09)70003-8 ID - Fenaux2009 ER - TY - JOUR AU - Gurion, R. AU - Vidal, L. AU - Gafter-Gvili, A. PY - 2010 DA - 2010// TI - 5-azacytidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis JO - Haematologica VL - 95 UR - https://doi.org/10.3324/haematol.2009.010611 DO - 10.3324/haematol.2009.010611 ID - Gurion2010 ER - TY - JOUR AU - Gore, S. D. AU - Fenaux, P. AU - Santini, V. PY - 2013 DA - 2013// TI - A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacytidine or conventional care regimens in the randomized AZA-001 trial JO - Haematologica VL - 98 UR - https://doi.org/10.3324/haematol.2012.074831 DO - 10.3324/haematol.2012.074831 ID - Gore2013 ER - TY - JOUR AU - Götze, K. AU - Platzbecker, U. AU - Giagounidis, A. PY - 2010 DA - 2010// TI - Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group JO - Ann Hematol VL - 89 UR - https://doi.org/10.1007/s00277-010-1015-0 DO - 10.1007/s00277-010-1015-0 ID - Götze2010 ER - TY - JOUR AU - Cogle, C. R. AU - Scott, B. L. AU - Boyd, T. AU - Garcia-Manero, G. PY - 2015 DA - 2015// TI - Oral Azacytidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia JO - Oncologist VL - 20 UR - https://doi.org/10.1634/theoncologist.2015-0165 DO - 10.1634/theoncologist.2015-0165 ID - Cogle2015 ER - TY - JOUR AU - Garcia-Manero, G. AU - Gore, S. D. AU - Cogle, C. PY - 2011 DA - 2011// TI - Phase I study of oral azacytidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.34.4226 DO - 10.1200/JCO.2010.34.4226 ID - Garcia-Manero2011 ER - TY - JOUR AU - Platzbecker, U. AU - Wermke, M. AU - Radke, J. PY - 2011 DA - 2011// TI - Azacytidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial JO - Leukemia VL - 26 UR - https://doi.org/10.1038/leu.2011.234 DO - 10.1038/leu.2011.234 ID - Platzbecker2011 ER - TY - JOUR AU - Schroeder, T. AU - Rachlis, E. AU - Bug, G. PY - 2015 DA - 2015// TI - Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacytidine and donor lymphocyte infusions - a retrospective multicenter analysis from the German Cooperative Transplant Study Group JO - Biol Blood Marrow Transplant VL - 21 UR - https://doi.org/10.1016/j.bbmt.2014.12.016 DO - 10.1016/j.bbmt.2014.12.016 ID - Schroeder2015 ER - TY - JOUR AU - Steensma, D. P. AU - Baer, M. R. AU - Slack, J. L. PY - 2009 DA - 2009// TI - Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.19.6550 DO - 10.1200/JCO.2008.19.6550 ID - Steensma2009 ER - TY - JOUR AU - Fenaux, P. AU - Mufti, G. J. AU - Hellström-Lindberg, E. PY - 2010 DA - 2010// TI - Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.23.8329 DO - 10.1200/JCO.2009.23.8329 ID - Fenaux2010 ER - TY - JOUR AU - Pleyer, L. AU - Burgstaller, S. AU - Girschikofsky, M. PY - 2014 DA - 2014// TI - Azacytidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacytidine Registry of the AGMT-Study Group JO - Ann Hematol VL - 93 UR - https://doi.org/10.1007/s00277-014-2126-9 DO - 10.1007/s00277-014-2126-9 ID - Pleyer2014 ER - TY - JOUR AU - Thépot, S. AU - Itzykson, R. AU - Seegers, V. PY - 2014 DA - 2014// TI - Azacitidine in untreated acute myeloid leukemia: a report on 149 patients JO - Am J Hematol VL - 89 UR - https://doi.org/10.1002/ajh.23654 DO - 10.1002/ajh.23654 ID - Thépot2014 ER - TY - JOUR AU - Dombret, H. AU - Seymour, J. F. AU - Butrym, A. PY - 2015 DA - 2015// TI - International phase 3 study of azacytidine vs conventional care regimens in older patients with newly diagnosed AML with >30 % blasts JO - Blood VL - 126 UR - https://doi.org/10.1182/blood-2015-01-621664 DO - 10.1182/blood-2015-01-621664 ID - Dombret2015 ER - TY - JOUR AU - Müller-Tidow, C. AU - Tschanter, P. AU - Röllig, C. PY - 2016 DA - 2016// TI - Azacytidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia JO - Leukemia VL - 30 UR - https://doi.org/10.1038/leu.2015.306 DO - 10.1038/leu.2015.306 ID - Müller-Tidow2016 ER - TY - JOUR AU - Kantarjian, H. AU - Thomas, X. G. AU - Dmoszynska, A. PY - 2012 DA - 2012// TI - Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.38.9429 DO - 10.1200/JCO.2011.38.9429 ID - Kantarjian2012 ER - TY - JOUR AU - Lee, Y. G. AU - Kim, I. AU - Yoon, S. S. PY - 2013 DA - 2013// TI - Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes JO - Br J Haematol VL - 161 UR - https://doi.org/10.1111/bjh.12256 DO - 10.1111/bjh.12256 ID - Lee2013 ER - TY - JOUR AU - Bejar, R. AU - Stevenson, K. AU - Abdel-Wahab, O. PY - 2011 DA - 2011// TI - Clinical effect of point mutations in myelodysplastic syndromes JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1013343 DO - 10.1056/NEJMoa1013343 ID - Bejar2011 ER - TY - JOUR AU - Haferlach, T. AU - Nagata, Y. AU - Grossmann, V. PY - 2014 DA - 2014// TI - Landscape of genetic lesions in 944 patients with myelodysplastic syndromes JO - Leukemia VL - 28 UR - https://doi.org/10.1038/leu.2013.336 DO - 10.1038/leu.2013.336 ID - Haferlach2014 ER - TY - JOUR AU - Papaemmanuil, E. AU - Gerstung, M. AU - Malcovati, L. PY - 2013 DA - 2013// TI - Clinical and biological implications of driver mutations in myelodysplastic syndromes JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-08-518886 DO - 10.1182/blood-2013-08-518886 ID - Papaemmanuil2013 ER - TY - JOUR AU - Fandy, T. E. AU - Herman, J. G. AU - Kerns, P. PY - 2009 DA - 2009// TI - Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2009-02-203547 DO - 10.1182/blood-2009-02-203547 ID - Fandy2009 ER - TY - JOUR AU - Qin, T. AU - Castoro, R. AU - Ahdab, S. PY - 2011 DA - 2011// TI - Mechanisms of resistance to decitabine in the myelodysplastic syndrome JO - PLoS One VL - 6 UR - https://doi.org/10.1371/journal.pone.0023372 DO - 10.1371/journal.pone.0023372 ID - Qin2011 ER - TY - JOUR AU - Valencia, A. AU - Masala, E. AU - Rossi, A. PY - 2014 DA - 2014// TI - Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacytidine JO - Leukemia VL - 28 UR - https://doi.org/10.1038/leu.2013.330 DO - 10.1038/leu.2013.330 ID - Valencia2014 ER - TY - JOUR AU - Bejar, R. AU - Lord, A. AU - Stevenson, K. PY - 2014 DA - 2014// TI - TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-06-582809 DO - 10.1182/blood-2014-06-582809 ID - Bejar2014 ER - TY - JOUR AU - Itzykson, R. AU - Kosmider, O. AU - Cluzeau, T. PY - 2011 DA - 2011// TI - Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias JO - Leukemia VL - 25 UR - https://doi.org/10.1038/leu.2011.71 DO - 10.1038/leu.2011.71 ID - Itzykson2011 ER - TY - JOUR AU - Traina, F. AU - Visconte, V. AU - Elson, P. PY - 2014 DA - 2014// TI - Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms JO - Leukemia VL - 28 UR - https://doi.org/10.1038/leu.2013.269 DO - 10.1038/leu.2013.269 ID - Traina2014 ER - TY - JOUR AU - Cluzeau, T. AU - Robert, G. AU - Mounier, N. PY - 2012 DA - 2012// TI - BCL2L10 is a predictive factor for resistance to azacytidine in MDS and AML patients JO - Oncotarget VL - 3 UR - https://doi.org/10.18632/oncotarget.481 DO - 10.18632/oncotarget.481 ID - Cluzeau2012 ER - TY - JOUR AU - Müller-Thomas, C. AU - Rudelius, M. AU - Rondak, I. -. C. PY - 2014 DA - 2014// TI - Response to azacytidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia JO - Haematologica VL - 2 UR - https://doi.org/10.3324/haematol.2014.104760 DO - 10.3324/haematol.2014.104760 ID - Müller-Thomas2014 ER - TY - JOUR AU - Meldi, K. AU - Qin, T. AU - Buchi, F. PY - 2015 DA - 2015// TI - Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia JO - J Clin Invest VL - 125 UR - https://doi.org/10.1172/JCI78752 DO - 10.1172/JCI78752 ID - Meldi2015 ER - TY - JOUR AU - Craddock, C. AU - Quek, L. AU - Goardon, N. PY - 2013 DA - 2013// TI - Azacytidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia JO - Leukemia VL - 27 UR - https://doi.org/10.1038/leu.2012.312 DO - 10.1038/leu.2012.312 ID - Craddock2013 ER - TY - JOUR AU - Merlevede, J. AU - Droin, N. AU - Qin, T. PY - 2016 DA - 2016// TI - Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms10767 DO - 10.1038/ncomms10767 ID - Merlevede2016 ER - TY - JOUR AU - Prebet, T. AU - Gore, S. D. AU - Esterni, B. PY - 2011 DA - 2011// TI - Outcome of High-Risk Myelodysplastic Syndrome After Azacytidine Treatment Failure JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2011.35.8135 DO - 10.1200/JCO.2011.35.8135 ID - Prebet2011 ER - TY - JOUR AU - Borthakur, G. AU - Ahdab, S. E. AU - Ravandi, F. PY - 2008 DA - 2008// TI - Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacytidine JO - Leuk Lymphoma VL - 49 UR - https://doi.org/10.1080/10428190701882146 DO - 10.1080/10428190701882146 ID - Borthakur2008 ER - TY - JOUR AU - Cameron, E. E. AU - Bachman, K. E. AU - Myohanen, S. PY - 1999 DA - 1999// TI - Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer JO - Nat Genet VL - 21 UR - https://doi.org/10.1038/5047 DO - 10.1038/5047 ID - Cameron1999 ER - TY - JOUR AU - Navada, S. C. AU - Steinmann, J. AU - Lübbert, M. AU - Silverman, L. R. PY - 2014 DA - 2014// TI - Clinical development of demethylating agents in hematology JO - J Clin Invest VL - 124 UR - https://doi.org/10.1172/JCI69739 DO - 10.1172/JCI69739 ID - Navada2014 ER - TY - JOUR AU - Sekeres, M. A. AU - Tiu, R. V. AU - Komrokji, R. PY - 2012 DA - 2012// TI - Phase 2 study of the lenalidomide and azacytidine combination in patients with higher-risk myelodysplastic syndromes JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-06-434639 DO - 10.1182/blood-2012-06-434639 ID - Sekeres2012 ER - TY - JOUR AU - Daver, N. AU - Kantarjian, H. AU - Ravandi, F. PY - 2016 DA - 2016// TI - A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome JO - Leukemia VL - 30 UR - https://doi.org/10.1038/leu.2015.244 DO - 10.1038/leu.2015.244 ID - Daver2016 ER - TY - JOUR AU - Nuthalapati, S. AU - Zhou, Q. AU - Guo, P. PY - 2012 DA - 2012// TI - Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy JO - Pharm Res VL - 29 UR - https://doi.org/10.1007/s11095-012-0780-y DO - 10.1007/s11095-012-0780-y ID - Nuthalapati2012 ER - TY - JOUR AU - Gangat, N. AU - Patnaik, M. M. AU - Tefferi, A. PY - 2016 DA - 2016// TI - Myelodysplastic syndromes: Contemporary review and how we treat JO - Am J Hematol VL - 91 UR - https://doi.org/10.1002/ajh.24253 DO - 10.1002/ajh.24253 ID - Gangat2016 ER - TY - JOUR AU - Fan, H. AU - Lu, X. AU - Wang, X. AU - Liu, Y. AU - Guo, B. PY - 2014 DA - 2014// TI - Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report JO - J Immunol Res VL - 2014 ID - Fan2014 ER - TY - JOUR AU - Juergens, R. A. AU - Wrangle, J. AU - Vendetti, F. P. PY - 2011 DA - 2011// TI - Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer JO - Cancer Discov VL - 1 UR - https://doi.org/10.1158/2159-8290.CD-11-0214 DO - 10.1158/2159-8290.CD-11-0214 ID - Juergens2011 ER - TY - JOUR AU - Nervi, C. AU - Marinis, E. AU - Codacci-Pisanelli, G. PY - 2015 DA - 2015// TI - Epigenetic treatment of solid tumours: a review of clinical trials JO - Clin Epigenetics VL - 7 UR - https://doi.org/10.1186/s13148-015-0157-2 DO - 10.1186/s13148-015-0157-2 ID - Nervi2015 ER -